Related Experiment Video

Updated: Jun 27, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer

Stephen J Assinder1, Qihan Dong, Zaklina Kovacevic

  • 1Discipline of Physiology, School of Medical Sciences and Bosch Institute Prostate Cancer Focus Group, University of Sydney, Sydney, New South Wales 2006, Australia.

The Biochemical Journal
|December 23, 2008
PubMed

Insights

Understanding integrated cancer pathways like TGF-beta, PI3K/Akt, and PTEN is crucial for developing targeted prostate cancer treatments. Genetic markers can personalize therapy, moving beyond a one-size-fits-all approach.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer treatment requires understanding complex biochemical pathways involved in tumor growth and suppression.
  • Prostate cancer's heterogeneity necessitates personalized treatment strategies over traditional methods.
  • Identifying genetic markers is key for predicting individual responses to targeted therapies.

Purpose of the Study:

  • To review the integration of three key pathways: TGF-beta, PI3K/Akt, and PTEN in cancer.
  • To discuss the role of gene polymorphisms and somatic mutations in these pathways.
  • To highlight novel pharmaceutical agents targeting these integrated pathways for cancer treatment.

Main Methods:

  • Literature review of evidence on the integration of TGF-beta, PI3K/Akt, and PTEN pathways.
  • Analysis of studies on gene polymorphisms and somatic mutations.
  • Identification and discussion of emerging pharmaceutical agents.

Main Results:

  • Evidence demonstrates the integration of tumor-suppressive (TGF-beta, PTEN) and tumorigenic (PI3K/Akt) pathways.
  • Gene alterations (polymorphisms, mutations) in these pathways are relevant to cancer development and progression.
  • Novel agents targeting key nodes within these integrated pathways are under investigation.

Conclusions:

  • Understanding pathway integration is vital for advancing cancer pharmacology.
  • Genetic profiling can guide personalized prostate cancer treatment.
  • Targeting integrated pathways offers promising avenues for novel cancer therapies.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...